Related Experiment Videos
T-cell subsets required for intravesical BCG immunotherapy for bladder cancer
T L Ratliff1, J K Ritchey, J J Yuan
1Washington University School of Medicine, Department of Pathology, St. Louis, Missouri.
The Journal of Urology
|September 1, 1993
Summary
Intravesical bacille Calmette-Guérin (BCG) therapy for bladder cancer requires both CD4 and CD8 T cells for antitumor activity. Depleting either T cell subset eliminates BCG
Area of Science:
- Immunology
- Oncology
- Urology
Background:
- Intravesical bacille Calmette-Guérin (BCG) is the standard treatment for superficial bladder cancer.
- The specific roles of CD4 and CD8 lymphocytes in BCG's antitumor response require further elucidation.
Purpose of the Study:
- To investigate the necessity of CD4 and CD8 T lymphocytes for BCG-mediated antitumor activity.
- To determine if delayed type hypersensitivity (DTH) is sufficient for BCG's antitumor effects.
Main Methods:
- Depletion of CD4 and CD8 T cell populations using monoclonal antibodies in mice.
- Verification of T cell depletion via flow cytometry.
- Administration of BCG therapy post-depletion and assessment of antitumor responses and DTH.
Main Results:
- Depletion of either CD4 or CD8 T cells abolished BCG's antitumor efficacy.
- CD4 depletion abrogated DTH, while CD8 depletion did not significantly alter it.
- DTH was insufficient for inducing BCG-mediated antitumor activity; IL-2 supplementation did not compensate for CD4 cells.
Conclusions:
- Both CD4 and CD8 T lymphocytes are essential for BCG's antitumor activity in superficial bladder cancer.
- BCG-mediated antitumor response is a localized effect and does not induce systemic protective immunity.